SQZ Biotechnologies Company (SQZB)
Market Cap | 825.75K |
Revenue (ttm) | 12.12M |
Net Income (ttm) | -71.64M |
Shares Out | 29.49M |
EPS (ttm) | -2.43 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,000 |
Average Volume | 386 |
Open | 0.0280 |
Previous Close | 0.0280 |
Day's Range | 0.0280 - 0.0280 |
52-Week Range | 0.0230 - 0.1000 |
Beta | 1.38 |
RSI | 46.29 |
Earnings Date | Aug 4, 2025 |
About SQZB
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC... [Read more]
Financial Performance
In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.
Financial StatementsNews

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotec...

Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its s...

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial resul...

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatme...

SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent p...

SQZ Biotechnologies Provides Update on Collaboration with Roche
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive s...